ClinicalTrials.gg

Program

TTYP01

A development code. Also written as “TTYP01 tables 60mg”, “TTYP01 tables 90mg” and “TTYP01 Tablets (12mg or 18mg)”.

Its studies are mostly in Alzheimer Disease · Autism Spectrum Disorder · Ischemic Stroke, led by Shanghai Auzone Biological Technology.

Furthest: phase 3, since Oct 15, 20245 company-led studies, 2 open or runningNext primary completion: Oct 23, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Shanghai Auzone Biological Technology52 open or runningphase 3since Oct 15, 2024Apr 18, 2020Oct 23, 2028phase 2 · NCT07252440

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 18, 2020First study: phase 1 study in Healthy Adult SubjectsFirst studyNCT04370431 · 72 enrolled · Australia
  2. Oct 16, 2023Phase 1 study in Healthy Adult SubjectsNCT06107205 · 29 enrolled · United States
  3. Oct 15, 2024Phase 3 study in Ischemic StrokeNCT06648304 · 614 enrolled · China
  4. Dec 25, 2024Phase 2 study in Autism Spectrum DisorderNCT06757504 · 150 planned · China
  5. Nov 14, 2025Phase 2 study in Alzheimer DiseaseNCT07252440 · 180 planned · China

Ahead

  1. Oct 23, 2028Primary completion: phase 2 study in Alzheimer DiseaseNCT07252440

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07252440Alzheimer Disease · China2RecruitingOct 23, 2028180
NCT06757504Autism Spectrum Disorder · China2RecruitingFeb 6, 2026150
NCT06648304Ischemic Stroke · China3CompletedJun 17, 2024614
NCT06107205Healthy Adult Subjects · United States1CompletedDec 14, 202329
NCT04370431Healthy Adult Subjects · Australia1CompletedDec 17, 202072

How it is read

Names in the registry

  • “TTYP01 tables 60mg”, 1 entry
  • “TTYP01 tables 90mg”, 1 entry
  • “TTYP01”, 1 entry
  • “TTYP01 Tablets (12mg or 18mg)”, 1 entry
  • “TTYP01 tablets”, 1 entry

Codes read as this program: TTYP01.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.